<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: It has been shown that the reversed operation of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> transporters when ATP levels fall accounts for most <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> release induced by severe <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) is formed after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and causes ATP <z:mpath ids='MPATH_63'>depletion</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Our purpose is to test if NO release from inducible NO synthase (iNOS) after <z:hpo ids='HP_0001297'>stroke</z:hpo> may cause a delayed <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> release due to ATP <z:mpath ids='MPATH_63'>depletion</z:mpath> that might underlie progression of the ischemic <z:mpath ids='MPATH_124'>infarct</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>We have studied the effect of the highly selective inhibitor of iNOS activity 1400W on brain ATP levels, extracellular <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi>, and <z:hpo ids='HP_0001297'>stroke</z:hpo> outcome after transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: To induce focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, the middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) was occluded by using the intraluminal thread technique (tMCAO) </plain></SENT>
<SENT sid="5" pm="."><plain>1400W was administered, after tMCAO, by using an Alzet osmotic pump to yield a drug delivery rate of 2.5 mg/kg/h </plain></SENT>
<SENT sid="6" pm="."><plain>Results </plain></SENT>
<SENT sid="7" pm="."><plain>Postischemic treatment with 1400W induced a reduction in the neurofunctional impairment and in the total volume of brain <z:mpath ids='MPATH_124'>infarct</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>Western blot analysis showed <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced expression of iNOS </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment with 1400W partially prevented delayed ATP reduction and produced inhibition of the subsequent delayed increase in <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> levels caused by the ischemic insult </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Our data indicate that 1400W improves <z:hpo ids='HP_0001297'>stroke</z:hpo> outcome, an effect concomitant to the inhibition of both <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced decrease in brain ATP levels and increase in <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> release </plain></SENT>
<SENT sid="11" pm="."><plain>These results provide evidence indicating that the expression of iNOS induced by <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> may contribute to the progression of the ischemic <z:mpath ids='MPATH_124'>infarct</z:mpath> and have important therapeutic implications for the management of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>